Cardiotoxicity of the new cancer therapeutics--mechanisms of, and approaches to, the problem.

Cardiotoxicity of the new cancer therapeutics--mechanisms of, and approaches to, the problem.
复制标题

DOI:
10.1016/j.drudis.2008.05.011
复制
发表时间:
2008-09
影响因子:
7.4
通讯作者:
Kerkelae, Risto
Kerkelae, Risto
中科院分区:
医学2区
文献类型:
--
作者:
Force, Thomas;Kerkelae, Risto

文献摘要

参考文献

被引文献

相似文献

一些靶向治疗药物(包括单克隆抗体和小分子抑制剂)的心脏毒性是现实。在这里,我们将研究它为什么会发生,重点是分子机制,以更好地理解这个问题。我们还将研究这个问题有多大,更重要的是,它在未来可能会变得多大。我们将审查在临床前阶段检测心脏毒性的模型。我们还将关注两个驱动心脏毒性的关键领域-多靶向和ATP竞争性拮抗剂固有的选择性缺乏。最后,我们将研究可逆性的问题,并讨论保持患者治疗的可能方法。
Cardiotoxicity of some targeted therapeutics, including monoclonal antibodies and small molecule inhibitors, is a reality. Herein we will examine why it occurs, focusing on molecular mechanisms to better understand the issue. We will also examine how big the problem is and, more importantly, how big it may become in the future. We will review models for detecting cardiotoxicity in the pre-clinical phase. We will also focus on two key areas that drive cardiotoxicity- multi-targeting and the inherent lack of selectivity of ATP-competitive antagonists. Finally, we will examine the issue of reversibility and discuss possible approaches to keeping patients on therapy.
DOI: 10.1056/nejmoa053028
发表时间: 2006-02-23
影响因子: 158.5
作者:
Joensuu, H;Kellokumpu-Lehtinen, P;Isola, J
通讯作者: Isola, J
DOI: 10.1161/01.hyp.0000215207.54689.31
发表时间: 2006-05-01
期刊: HYPERTENSION
影响因子: 8.3
作者:
Izumiya, Y;Shiojima, I;Walsh, K
通讯作者: Walsh, K
DOI: 10.1056/nejmoa055104
发表时间: 2006-06-15
影响因子: 158.5
作者:
Kantarjian, Hagop;Giles, Francis;Ottmann, Oliver G.
通讯作者: Ottmann, Oliver G.
DOI: 10.1200/jco.2005.13.300
发表时间: 2005-11-01
影响因子: 45.3
作者:
Ewer, MS;Vooletich, MT;Lenihan, DJ
通讯作者: Lenihan, DJ
DOI: 10.1172/jci32373
发表时间: 2007-12-01
影响因子: 15.9
作者:
Fernandez, Ariel;Sanguino, Angela;Lopez-Berestein, Gabriel
通讯作者: Lopez-Berestein, Gabriel